R&J Public Relations Named Agency of Record for Aerocrine, Inc.
BRIDGEWATER, N.J., Jan. 25, 2011 /PRNewswire/ — Aerocrine, Inc., an innovative medical technology company focused on the treatment of patients with inflamed airways, has selected R&J Public Relations, LLC of Bridgewater, N.J., as its public relations agency of record. R&J will conduct strategic public relations for the Aerocrine brand; most immediately surrounding the NIOX MINOÃ‚®, the first and only hand-held device available to measure exhaled nitric oxide (eNO) to aid in asthma management in the United States.
For the first time ever, The NIOX MINO provides doctors the ability to more effectively diagnose, monitor and optimize therapy for individuals suffering from inflammatory airway diseases through one easy-to-use device. This ground-breaking technology helps eliminate the uncertainties that contribute to asthma morbidity and mortality, including incorrect diagnosis, patient adherence issues, and identifying those patients that will be responsive to treatment.
“Our comprehensive experience and strong presence in the healthcare market space combined with our aggressive and proactive consumer and media relations practices will provide Aerocrine with the leverage they need to elevate their innovative brand and products,” said Scott Marioni, Executive Vice President of R&J Public Relations. “R&J is confident that our strategic public relations will significantly increase the awareness of the Aerocrine brand and NIOX MINO while positioning eNO testing as a standard for patients with asthmatic symptoms.”
The founders of Aerocrine originated from the Karolinska Institute in Sweden where they first discovered the significant tie between nitric oxide (NO) and inflammation. Aerocrine used this discovery as a basis for creating products that assist in the management and care of people afflicted with varying airway inflammatory diseases.
R&J’s main objective is to promptly elevate Aerocrine’s brand through its established world-wide reputation, and further the awareness of Aerocrine’s NIOX MINO products among allergists, pulmonologists, and potential patients. Through a decisive, long-term plan, combined with steadfast public and media relations efforts, R&J will support Aerocrine’s growth and product-specific goal.
Aerocrine AB is a medical technology company focused on the improved management and care of patients with inflammatory airway diseases. As the pioneer and leader in the technology to monitor and manage airway inflammation, Aerocrine markets NIOXÃ‚® Flex and NIOX MINOÃ‚®. Both products enable fast and reliable management of airway inflammation and may therefore play a critical role in more effective diagnosis, treatment and follow-up of patients with inflammatory airway diseases such as asthma. Aerocrine is based in Sweden with subsidiaries in the US, Germany and the UK. Aerocrine shares were listed on the Stockholm Stock Exchange on 15 June 2007. More information can be found online at www.aerocrine.com.
About R&J Public Relations
R&J Public Relations, LLC is a full-service public relations firm that consistently achieves superior results for a strong and diverse client base that ranges from divisions of large, multi-national conglomerates to regional market leaders. Based in Bridgewater, N.J., with an office in Manhattan, the company has become one of the most respected, admired and prestigious PR agencies in the Greater New York/New Jersey region. R&J has earned numerous awards for its strategic communications programs and was named a “Top Place to Work in PR” by PR News in 2010. For more information on R&J Public Relations, please visit www.randjpr.com.
SOURCE R&J Public Relations, LLC